A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
317actual
Sites
154
Countries
Argentina, Australia, Bulgaria +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor Decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-24 | actual | When the study began enrolling |
| Primary completion | 2026-05-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-23 | actual | The whole study's end, after follow-up |
| First posted | 2024-04-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Interventions
- Drug: Rocatinlimab — also filed as AMG 451
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFAnnualized Rate of Composite Endpoint for Exacerbations (CompEx) Events During the Blinded Treatment Period
measured Up to Week 48
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed